Erste Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Erste Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-249	Closed	-$443K	–	445
2018 Q4	$443K	Buy	+249	New	+$542K	0.03%	318

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Erste Asset Management's ACOR Position: Q1 2019 in Review

Erste Asset Management sold out of Acorda Therapeutics (ACOR) in Q1 2019, closing a stake of 249 shares — an estimated $443K sold.

Erste Asset Management first reported a position in ACOR in Q4 2018 and held it in 1 quarter. The position peaked at $443K in Q4 2018. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

Erste Asset Management reported no remaining Acorda Therapeutics position as of Q1 2019 after selling out during the quarter.
Erste Asset Management sold 249 Acorda Therapeutics shares in Q1 2019, an estimated $443K.
Erste Asset Management first reported a position in Acorda Therapeutics in Q4 2018 and held it in 1 quarter.
Erste Asset Management's Acorda Therapeutics position peaked at $443K in Q4 2018.
184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on Erste Asset Management's 13F filing for Q1 2019, filed 22 Nov 2024.